Incretin-based Therapy Plus a Structured Lifestyle Plan for Obesity
Official title: Holistic Approach to Cardiometabolic Health and Obesity: Incretin-based Therapies, Nutrition, and Active Lifestyle
Run by Laval University · NCT07409831 · Data updated 2026-11-12
This study tests whether adding a six-month supervised exercise and nutrition program to prescribed incretin-based weight‑loss medication helps preserve muscle and physical function in adults with obesity, compared with medication alone.
Quick facts
| Study type | Interventional |
|---|---|
| Ages | 18 Years to 70 Years |
| Sex | All |
| Enrollment | 120 (estimated) |
| Sponsor | Laval University Academic / other |
| Locations | 2 sites (Québec, Quebec and 1 other locations) |
| Status | Recruiting |
| Started | July 6, 2026 |
| Main results expected | March 2028 |
| Study ends | March 2028 |
| Registry record updated | July 16, 2026 |
| Trial ID | NCT07409831 on ClinicalTrials.gov |
Is this trial a fit for you?
✓Likely a good fit
Ideal candidates are adults 18–70 with obesity (BMI >30, or BMI >27 with a comorbidity) who have not yet started incretin-based therapy and are able to participate in supervised exercise.
✕Probably not a fit
Individuals unable to safely engage in physical activity or who respond to medication but not to lifestyle support may see limited additional benefit.
A plain-English reading of the study's rules. Only the study team can confirm whether you qualify.
What this trial studies
This one-year pilot study in adults with obesity will enroll 120 participants who are about to start incretin-based pharmacotherapy as part of routine care. Participants will be randomized to receive either the standard medication alone or medication plus a six‑month structured lifestyle program that includes supervised strength-focused exercise and bi‑monthly nutrition counseling, followed by a maintenance phase. The trial aims to evaluate muscle mass preservation, physical function, and the feasibility of a hospital‑community care collaboration. Outcomes will inform whether combining pharmacotherapy with lifestyle support improves outcomes beyond medication alone.
Why it matters
Potential benefit: If successful, participants may experience better preservation of muscle mass and physical function during weight loss, enhancing overall health and mobility.
How similar studies have gone: Previous approaches combining pharmacotherapy with lifestyle components have shown promise, but this specific pairing with a structured hospital–community program and muscle-preservation outcomes is relatively novel.
Who can join: the full rules
Show full inclusion / exclusion criteria
Inclusion Criteria: * Adults aged 18 to 70 years * Prescribed, but not yet initiated, incretin-based pharmacotherapy \[e.g., GLP-1 receptor agonist or dual GIP/GLP1 agonist\] living with obesity, defined as: * BMI \>30 kg/m2, or * BMI \>27 kg/m2 with presence of comorbidities (e.g., type II diabetes, hypertension, hypercholesterolemia) Exclusion Criteria: * Medical contraindications to physical activity practice (e.g., unstable cardiovascular disease, severe orthopedic limitation) * Prior or ongoing incretin-based therapy or history of bariatric surgery * Pregnancy, current breastfeeding or planned pregnancy during the study period * Implemented medical devices (e.g. pacemaker, defibrillator) * Chronic conditions affecting protein metabolism or nutrition (e.g., advanced kidney disease, active cancer)
Where it's running
-
Institut universitaire de cardiologie et de pneumologie de Québec - Université Laval
Québec, Quebec, Canada Recruiting -
Institut universitaire de cardiologie et de pneumologie de Québec - Université Laval
Québec, Quebec, Canada Not yet recruiting
Study contacts
- Principal investigator: Andréanne Michaud, DtP, PhD — Institut universitaire de cardiologie et de pneumologie de Québec, University Laval
- Study coordinator: Elisa Marin-Couture, Kin, PhD
- Email: elisa.marin-couture.1@ulaval.ca
- Phone: 1-418-656-8711
Similar studies
Other studies for the same condition or treatment. Recruiting studies are listed first.
-
How incretin treatments affect muscle mass and function in people with overweight or obesity
This study will see how drugs like semaglutide and tirzepatide influence fat-free mass, muscle strength, and physical function in adults with overweight or obesity.
-
Dose find for remimazolam plus alfentanil for gastroscopy in obese adults
This trial tests what dose of remimazolam besylate with alfentanil best sedates obese adults during gastroscopy.
-
Two-Year Weight Loss With GLP-1 Medications Compared With Sleeve Gastrectomy in Adults
This study compares how much weight adults lose over two years when starting GLP-1 medicines versus adults who had sleeve gastrectomy at the same center.
-
Gut barrier and inflammation after fast-food overfeeding in adults
This study tests whether 14 days of fast-food overfeeding can alter gut barrier function and trigger inflammation in adults who are generally healthy.
-
High BMI and periodontitis in Thai adults under 60
This study tests how common high BMI and periodontitis are among Thai adults aged 18–59 and what factors are linked to them.
-
GLP-1 weight‑loss medicine: finding who will benefit most
This study tests whether a GLP-1 drug called semaglutide helps with weight loss by changing eating behavior, to see which people it helps the most.
How to take part
- Review the eligibility criteria above with your treating physician.
- Check the official listing on ClinicalTrials.gov for the latest contact details and recruitment status.
- Contact the study coordinator or principal investigator to ask for pre-screening. Pre-screening is free and never obligates you to enroll.